Home Featured Page 242

Featured

Latest

Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic Summit (Part 2)

Colorado’s Psilocybin Supply Chain Complete: First Testing Lab Licensed, Sessions Could Begin This Month

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First Look at Gilgamesh’s Phase 2a Data; ASCP 2025 Preview; VA Sec. Pressed on...

EXCLUSIVE: Heroic Hearts and Healing Breakthrough Merge to Expand Stateside Psychedelic Access for Veterans

Ibogaine – The Promise, the Protocol, and Protecting the Sacred

Braxia Scientific Introduces “Braxia Health” a Growing Network of Clinics Leading...

Entheon Biomedical Lists on OTCQB Venture Market

Red Light Holland Receives Patent Pending Status For ‘Find Your Dose’...

Mydecine Announces Partnership with LeadGen Labs

MindMed Announces Project Angie, Targeting the Treatment of Pain with Psychedelics

Small Pharma Inc. to Commence Trading on the TSX Venture Exchange...

Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural...

Lobe Sciences Acquires Vitamind Line of Wellness Products

PT242 – Gary Laderman – Religion: Sex, Death, and Drugs

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in...

1...241242243...286 Page 242 of 286

EDITOR PICKS

Dispatch from Breaking Convention 2025: Key Takeaways from Europe’s Largest Psychedelic...

Colorado’s Psilocybin Supply Chain Complete: First Testing Lab Licensed, Sessions Could...

Pα+ Psychedelic Bulletin #196: Otsuka Eyes Psychedelic Future in Japan; First...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.